South Rampart Pharma Publishes SRP-001's Unique Pain Relief Mechanism and Phase 1 Trial Results in Scientific Reports
NEW ORLEANS, May 16, 2024 (GLOBE NEWSWIRE) -- South Rampart Pharma, Inc., today announced the publication of a paper in Scientific Reports describing the manner in which SRP-001 works in the brain to alleviate pain and the results of a Phase 1 randomized controlled trial (RCT)1.
- NEW ORLEANS, May 16, 2024 (GLOBE NEWSWIRE) -- South Rampart Pharma, Inc., today announced the publication of a paper in Scientific Reports describing the manner in which SRP-001 works in the brain to alleviate pain and the results of a Phase 1 randomized controlled trial (RCT)1.
- The study, by Bazan et al., is titled, " Transcriptomic signature, bioactivity and safety of a non-hepatotoxic analgesic generating AM404 in the midbrain PAG region ."
- The publication reveals SRP-001's unique mechanism of action, producing higher amounts of N-arachidonoylphenolamine (AM404) than acetaminophen, a metabolite crucial for inducing pain relief in the midbrain’s periaqueductal grey (PAG) region.
- Armed with known mechanisms for pain relief in the brain and compelling Phase 1 randomized trial data, we look forward to advancing SRP-001 into Phase 2 randomized and controlled studies for acute and neuropathic pain in the second half of 2024.”